N A Terrault

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi request reprint Sexual transmission of hepatitis C virus among monogamous heterosexual couples: the HCV partners study
    Norah A Terrault
    Department of Medicine, University of California San Francisco, San Francisco, CA 94143, USA
    Hepatology 57:881-9. 2013
  2. doi request reprint Liver transplantation in the setting of chronic HCV
    Norah Terrault
    University of California San Francisco, United States
    Best Pract Res Clin Gastroenterol 26:531-48. 2012
  3. pmc Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection
    Norah A Terrault
    University of California San Francisco, 513 Parnassus Avenue, San Francisco, CA 94143, USA
    Liver Transpl 18:716-26. 2012
  4. ncbi request reprint Clinical utility of viral load measurements in individuals with chronic hepatitis C infection on antiviral therapy
    N A Terrault
    Division of Gastroenterology, Department of Medicine, University of California San Francisco, San Francisco, CA 94143 0538, USA
    J Viral Hepat 12:465-72. 2005
  5. ncbi request reprint Treatment of recurrent hepatitis C in liver transplant recipients
    Norah A Terrault
    Division of Gastroenterology, University of California at San Francisco, San Francisco, CA 94143 0538, USA
    Clin Gastroenterol Hepatol 3:S125-31. 2005
  6. ncbi request reprint Outcome of patients with hepatitis B virus and human immunodeficiency virus infections referred for liver transplantation
    Norah A Terrault
    Department of Medicine, University of California at San Francisco, San Francisco, CA 64143 0538, USA
    Liver Transpl 12:801-7. 2006
  7. ncbi request reprint Treating hepatitis C infection in liver transplant recipients
    Norah A Terrault
    Department of Medicine Gastroenterology, University of California San Francisco, San Francisco, CA, USA
    Liver Transpl 12:1192-204. 2006
  8. doi request reprint Benefits and risks of combination therapy for hepatitis B
    Norah A Terrault
    Departments of Medicine and Surgery, University of California San Francisco, San Francisco, CA 94143 0538, USA
    Hepatology 49:S122-8. 2009
  9. pmc Fibrosis progression in African Americans and Caucasian Americans with chronic hepatitis C
    Norah A Terrault
    Department of Medicine, University of California San Francisco, San Francisco, California 94143 0538, USA
    Clin Gastroenterol Hepatol 6:1403-11. 2008
  10. doi request reprint Hepatitis C therapy before and after liver transplantation
    Norah A Terrault
    Division of Gastroenterology, Department of Medicine, University of California San Francisco, San Francisco, CA 94143, USA
    Liver Transpl 14:S58-66. 2008

Research Grants

Collaborators

Detail Information

Publications61

  1. ncbi request reprint Sexual transmission of hepatitis C virus among monogamous heterosexual couples: the HCV partners study
    Norah A Terrault
    Department of Medicine, University of California San Francisco, San Francisco, CA 94143, USA
    Hepatology 57:881-9. 2013
    ..07% per year (95% confidence interval, 0.01-0.13) or approximately one per 190,000 sexual contacts. No specific sexual practices were related to HCV positivity among couples...
  2. doi request reprint Liver transplantation in the setting of chronic HCV
    Norah Terrault
    University of California San Francisco, United States
    Best Pract Res Clin Gastroenterol 26:531-48. 2012
    ....
  3. pmc Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection
    Norah A Terrault
    University of California San Francisco, 513 Parnassus Avenue, San Francisco, CA 94143, USA
    Liver Transpl 18:716-26. 2012
    ..Our results indicate that HCV per se is not a contraindication to LT in HIV patients, but recipient and donor selection and the management of acute rejection strongly influence outcomes...
  4. ncbi request reprint Clinical utility of viral load measurements in individuals with chronic hepatitis C infection on antiviral therapy
    N A Terrault
    Division of Gastroenterology, Department of Medicine, University of California San Francisco, San Francisco, CA 94143 0538, USA
    J Viral Hepat 12:465-72. 2005
    ..Additionally, we demonstrated the need for cautious interpretation of stopping rules when the values are at or near the decision thresholds...
  5. ncbi request reprint Treatment of recurrent hepatitis C in liver transplant recipients
    Norah A Terrault
    Division of Gastroenterology, University of California at San Francisco, San Francisco, CA 94143 0538, USA
    Clin Gastroenterol Hepatol 3:S125-31. 2005
    ..Overall, the treatment of HCV disease in transplant recipients leaves much to be desired and there is an urgent need of new HCV therapies in this patient population...
  6. ncbi request reprint Outcome of patients with hepatitis B virus and human immunodeficiency virus infections referred for liver transplantation
    Norah A Terrault
    Department of Medicine, University of California at San Francisco, San Francisco, CA 64143 0538, USA
    Liver Transpl 12:801-7. 2006
    ..In HIV-HBV coinfected patients undergoing LT, HBV recurrence is successfully prevented with combination prophylaxis using HBIG and antivirals...
  7. ncbi request reprint Treating hepatitis C infection in liver transplant recipients
    Norah A Terrault
    Department of Medicine Gastroenterology, University of California San Francisco, San Francisco, CA, USA
    Liver Transpl 12:1192-204. 2006
    ..Liver Transpl 12:1192-1204, 2006. (c) 2006 AASLD...
  8. doi request reprint Benefits and risks of combination therapy for hepatitis B
    Norah A Terrault
    Departments of Medicine and Surgery, University of California San Francisco, San Francisco, CA 94143 0538, USA
    Hepatology 49:S122-8. 2009
    ..There is insufficient evidence to recommend combination therapy as first-line therapy for all patients with chronic hepatitis B...
  9. pmc Fibrosis progression in African Americans and Caucasian Americans with chronic hepatitis C
    Norah A Terrault
    Department of Medicine, University of California San Francisco, San Francisco, California 94143 0538, USA
    Clin Gastroenterol Hepatol 6:1403-11. 2008
    ..Prior studies suggest the rate of liver fibrosis progression is slower in African Americans (AAs) than Caucasian Americans (CAs) with chronic HCV infection...
  10. doi request reprint Hepatitis C therapy before and after liver transplantation
    Norah A Terrault
    Division of Gastroenterology, Department of Medicine, University of California San Francisco, San Francisco, CA 94143, USA
    Liver Transpl 14:S58-66. 2008
    ..6. Hepatitis C virus-infected liver transplant recipients represent an important patient population in need of new therapeutics options to prevent patient and graft losses due to recurrent hepatitis C virus disease...
  11. ncbi request reprint The kidney transplant recipient with hepatitis C infection: pre- and posttransplantation treatment
    Norah A Terrault
    Department of Medicine, Division of Gastroenterology, University of California, San Francisco, San Francisco, California, USA
    Clin J Am Soc Nephrol 2:563-75. 2007
    ..New antiviral agents that can be used in dialysis patients (e.g., ribavirin alternatives) and in the posttransplantation setting (e.g., IFN alternatives) are needed to improve outcomes in these populations...
  12. ncbi request reprint Molecular characterization of intrahepatic and extrahepatic hepatitis B virus (HBV) reservoirs in patients on suppressive antiviral therapy
    C S Coffin
    Liver Unit, Division of Gastroenterology, Department of Medicine, Faculty of Medicine, University of Calgary, AB, Canada
    J Viral Hepat 18:415-23. 2011
    ..PBMC may be a sanctuary for wt virus during antiviral therapy, while the liver harbours more drug-resistant viruses. Drug resistance correlates with intrahepatic viral diversity...
  13. pmc Virologic and clinical outcomes of hepatitis B virus infection in HIV-HBV coinfected transplant recipients
    C S Coffin
    Department of Medicine, University of California San Francisco, San Francisco, CA, USA
    Am J Transplant 10:1268-75. 2010
    ..Combination HBIG and antivirals is effective as prophylaxis with no clinical evidence of HBV recurrence but low-level HBV DNA is detectable in approximately 50% of recipients...
  14. ncbi request reprint Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1
    Hari S Conjeevaram
    Division of Gastroenterology, The University of Michigan, Ann Arbor, Michigan 48109 0362, USA
    Gastroenterology 131:470-7. 2006
    ..Compared with Caucasian Americans (CA), African Americans (AA) with chronic hepatitis C are less likely to respond to interferon-based antiviral therapy...
  15. ncbi request reprint Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation
    Amandeep K Shergill
    Department of Medicine, University of California San Francisco, San Francisco, CA, USA
    Am J Transplant 5:118-24. 2005
    ..Future studies should focus on alternative dosing schedules with more aggressive use of adjuvant therapies, including GFs...
  16. ncbi request reprint HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes
    M E Roland
    University of California, San Francisco, CA, USA
    Am J Transplant 8:355-65. 2008
    ....
  17. ncbi request reprint Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort
    F Y Yao
    Department of Medicine, Division of Gastroenterology, University of California, San Francisco, CA 94143 0538, USA
    Hepatology 34:411-6. 2001
    ..However, the small sample size and the use of a retrospective control cohort preclude drawing definitive conclusions. Expedited OLT remains the only viable treatment for lamivudine nonresponders...
  18. pmc Patient, center and geographic characteristics of nationally placed livers
    J C Lai
    Department of Medicine, Division of Gastroenterology and Hepatology, University of California San Francisco, San Francisco, CA, USA
    Am J Transplant 12:947-53. 2012
    ..These findings provide the foundation for a more informed discussion about changing our current liver allocation and distribution policies...
  19. pmc Gender differences in liver donor quality are predictive of graft loss
    J C Lai
    Department of Medicine, Division of Gastroenterology and Hepatology, University of California San Francisco, San Francisco, CA, USA
    Am J Transplant 11:296-302. 2011
    ....
  20. ncbi request reprint Management of hepatitis C in liver transplant recipients
    A Kuo
    Division of Gastroenterology, University of California San Francisco, San Francisco, CA, USA
    Am J Transplant 6:449-58. 2006
    ..Ongoing studies may establish a future role for alternative treatment approaches. Additionally, limited overall efficacy of interferon-based therapy in the transplant setting highlights the urgent need for new drug therapies...
  21. ncbi request reprint Hepatitis C etiology of liver disease is strongly associated with early acute rejection following liver transplantation
    Ryan A McTaggart
    Department of Surgery, Division of Transplantation, University of California San Francisco, San Francisco, CA 94143 0780, USA
    Liver Transpl 10:975-85. 2004
    ..Alternatively, the association of HCV and EAR may result from an increased frequency of allograft biopsy and may be further exacerbated by inability to accurately diagnose EAR in the setting of recurrent HCV...
  22. ncbi request reprint Treatment of recurrent hepatitis C after liver transplantation
    Scott W Biggins
    Division of Gastroenterology, Department of Medicine, University of California, San Francisco, 513 Parnassus Ave, S357, Box 0538 San Francisco, CA 94143, USA
    Clin Liver Dis 9:505-23, ix. 2005
    ..Prophylactic and preemptive therapies, as well as treatment of established recurrent disease, are the strategies reviewed...
  23. ncbi request reprint Antiviral therapy in patients with chronic hepatitis B and cirrhosis
    Cindy J Lai
    Division of General Internal Medicine, University of California San Francisco, S357, 513 Parnassus Avenue, San Francisco, CA 94143 0538, USA
    Gastroenterol Clin North Am 33:629-54, x-xi. 2004
    ..The newest oral nucleotide analog, adefovir dipivoxil, has shown excellent efficacy in treatment-naïve and lamivudine-resistant HBV patients and has lower rates of resistance in the short-term...
  24. doi request reprint Long-term histological effects of preemptive antiviral therapy in liver transplant recipients with hepatitis C virus infection
    Alexander Kuo
    Division of Gastroenterology, University of California, San Diego, CA, USA
    Liver Transpl 14:1491-7. 2008
    ..004). We conclude that preemptive antiviral therapy in virologic nonresponders delays the time to subsequent HCV treatment and may confer a reduced risk of fibrosis progression. Further study of preemptive antiviral therapy is warranted...
  25. pmc Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation
    Norah A Terrault
    Department of Medicine, Division of Gastroenterology, University of California at San Francisco, San Francisco, CA, USA
    Liver Transpl 13:122-9. 2007
    ..Important predictors of graft loss in HCV-infected patients were limited LDLT experience, pretransplant HCC, and higher MELD at transplantation...
  26. ncbi request reprint Serum sodium predicts mortality in patients listed for liver transplantation
    Scott W Biggins
    Department of Medicine, University of California San Francisco, San Francisco, CA 94143, USA
    Hepatology 41:32-9. 2005
    ..Addition of serum sodium to MELD increases the ability to predict 3- and 6-month mortality in patients with cirrhosis...
  27. pmc Multicenter evaluation of the performance characteristics of the bayer VERSANT HCV RNA 3.0 assay (bDNA)
    Tarek Elbeik
    Department of Laboratory Medicine, University of California, San Francisco 94110, USA
    J Clin Microbiol 42:563-9. 2004
    ..1%), a fold change of 2.6. Thus, the observed fold change between any two consecutive HCV RNA measures is expected to be less than 2.6-fold (equivalent to 0.41 log(10) IU/ml) 95% of the time in clinically stable individuals...
  28. pmc Influence of cannabis use on severity of hepatitis C disease
    Julie H Ishida
    Department of Medicine, University of California at San Francisco, San Francisco, California, USA
    Clin Gastroenterol Hepatol 6:69-75. 2008
    ..Complications of HCV infection are primarily related to the development of advanced fibrosis and whether cannabis use is a risk factor for more severe fibrosis is controversial...
  29. ncbi request reprint Treatment of recurrent hepatitis B infection in liver transplant recipients
    Norah A Terrault
    University of California, San Francisco, CA 64143 0538, USA
    Liver Transpl 8:S74-81. 2002
    ..6. Antiviral therapy with two or more suitable agents may minimize the chance for viral resistance; therefore, future therapeutic strategies likely will use combination therapy in the long-term management of recurrent HBV disease...
  30. ncbi request reprint Sexual activity as a risk factor for hepatitis C
    Norah A Terrault
    Gastroenterology Division, Department of Medicine, University of California, San Francisco, CA 94143, USA
    Hepatology 36:S99-105. 2002
    ..Current recommendations about sexual practices are different for persons with chronic HCV infection who are in steady monogamous partnerships versus those with multiple partners or who are in short-term sexual relationships...
  31. doi request reprint Is recurrent hepatitis C worse with living donors?
    Alexander Kuo
    Division of Gastroenterology, University of California, San Diego, 200 West Arbor Drive M C 8413, San Diego, CA 92103, USA
    Curr Opin Organ Transplant 14:240-4. 2009
    ..This review will present the current data regarding whether recurrent HCV is worse with living donors...
  32. ncbi request reprint Alcohol use and hepatitis C
    Marion G Peters
    Department of Gastroenterology, University of California, San Francisco, CA 94143, USA
    Hepatology 36:S220-5. 2002
    ..The literature is inadequate to provide definitive recommendations regarding the effect of light to moderate alcohol use in patients with hepatitis C...
  33. ncbi request reprint Organ donors with positive viral serology or malignancy: risk of disease transmission by transplantation
    Sandy Feng
    Department of Surgery, Division of Transplantation, University of California, San Francisco, San Francisco, CA 94143 0780, USA
    Transplantation 74:1657-63. 2002
  34. ncbi request reprint Pharmacokinetics of tacrolimus co-administered with adefovir dipivoxil to liver transplant recipients
    Norah A Terrault
    Department of Medicine and Surgery, University of California San Francisco, San Francisco, CA 94143 0538, USA
    Liver Int 29:1178-83. 2009
    ..Calcineurin inhibitors are a central component of immunosuppressive therapy...
  35. ncbi request reprint Management of hepatitis C-infected liver transplant recipients at large North American centres: changes in recent years
    Mandana Khalili
    Department of Medicine, University of California, San Francisco, CA 94110, USA
    Clin Transplant 20:1-9. 2006
    ..We conclude that there is considerable variability in the management of HCV among transplant programs and over time...
  36. ncbi request reprint New onset diabetes mellitus after liver transplantation: the critical role of hepatitis C infection
    Mandana Khalili
    Department of Medicine, University of California San Francisco, San Francisco, CA 94110, USA
    Liver Transpl 10:349-55. 2004
    ..However, among those developing de novo persistent diabetes, HCV is one of the most important risk factors. This adds further support to the epidemiological data linking HCV and diabetes...
  37. ncbi request reprint Hepatitis B immune globulin preparations and use in liver transplantation
    Norah A Terrault
    Department of Medicine, University of California, 513 Parnassus Avenue, Room S 537, San Francisco, CA 94143 0538, USA
    Clin Liver Dis 7:537-50. 2003
    ..Thus, there remains a need to develop and test new forms of anti-HBs therapy, so that effective but less expensive forms of immunoprophylaxis can be made available...
  38. ncbi request reprint Prophylactic and preemptive therapies for hepatitis C virus-infected patients undergoing liver transplantation
    Norah A Terrault
    University of California San Francisco, San Francisco, CA 64153, USA
    Liver Transpl 9:S95-S100. 2003
    ..4. It is unclear whether the preemptive antiviral treatment is superior to delaying treatment until recurrent disease is present and controlled trials addressing this issue are needed...
  39. ncbi request reprint Kidney and liver transplantation in HIV-infected patients: case presentations and review
    Michelle E Roland
    Department of Medicine, University of California, San Francisco, San Francisco, California, USA
    AIDS Patient Care STDS 17:501-7. 2003
    ....
  40. ncbi request reprint Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study
    Peter G Stock
    Department of Surgery, Division of Transplantation, University of California, San Francisco, California 94143 0780, USA
    Transplantation 76:370-5. 2003
    ....
  41. ncbi request reprint Frailty predicts waitlist mortality in liver transplant candidates
    J C Lai
    Division of Gastroenterology and Hepatology, Department of Medicine, University of California San Francisco, San Francisco, CA
    Am J Transplant 14:1870-9. 2014
    ..Frailty is prevalent in liver transplant candidates. It strongly predicts waitlist mortality, even after adjustment for liver disease severity demonstrating the applicability and importance of the frailty construct in this population. ..
  42. ncbi request reprint Evidence-based incorporation of serum sodium concentration into MELD
    Scott W Biggins
    University of California San Francisco, San Francisco, California, USA
    Gastroenterology 130:1652-60. 2006
    ..Serum sodium (Na) concentrations have been suggested as a useful predictor of mortality in patients with end-stage liver disease awaiting liver transplantation...
  43. pmc Height contributes to the gender difference in wait-list mortality under the MELD-based liver allocation system
    J C Lai
    Division of Gastroenterology and Hepatology, University of California, San Francisco, CA, USA
    Am J Transplant 10:2658-64. 2010
    ..Height contributes to this gender disparity, possibly reflecting differences in transplantation rates for shorter individuals...
  44. ncbi request reprint Management of hepatitis B in liver transplant recipients
    Carla S Coffin
    Department of Medicine, University of California at San Francisco, San Francisco, CA 94143, USA
    J Viral Hepat 14:37-44. 2007
    ..There is an increasing need for individualization of therapy based on prior drug exposures, level of HBV DNA at time of transplantation and type of prophylaxis used...
  45. pmc Addition of adult-to-adult living donation to liver transplant programs improves survival but at an increased cost
    Patrick G Northup
    Department of Medicine, University of Virginia, Charlottesville, VA, USA
    Liver Transpl 15:148-62. 2009
    ..The addition of LDLT to a standard waiting list DDLT program is effective at improving recipient survival and preventing waiting list deaths but at a greater cost...
  46. ncbi request reprint Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis
    Derek Patel
    Division of Gastroenterology, Department of Medicine, University of California, 513 Parnassus Avenue, San Francisco, CA 94143 0538, USA
    Clin Gastroenterol Hepatol 3:75-84. 2005
    ..Surveillance might detect HCC at a treatable stage. We estimated the clinical and economic consequences of a common HCC surveillance strategy in patients with HCV-related cirrhosis in the context of alternative HCC treatment strategies...
  47. pmc A comparison of measured and calculated free 25(OH) vitamin D levels in clinical populations
    J B Schwartz
    Departments of Medicine J B S, J L, B L, N A T, D B, Bioengineering and Therapeutic Sciences J B S, S M, Physiological Nursing P W, Obstetrics and Gynecology N S, and Dermatology D B, University of California San Francisco, San Francisco, California 94143 and Jewish Home of San Francisco J B S, L K, San Francisco, California 94112
    J Clin Endocrinol Metab 99:1631-7. 2014
    ....
  48. pmc Mutation of human keratin 18 in association with cryptogenic cirrhosis
    N O Ku
    Department of Medicine, VA Palo Alto Health Care System, California 94304, USA
    J Clin Invest 99:19-23. 1997
    ..Our results suggest that mutations in K18 may be predispose to, or result in cryptogenic cirrhosis in humans...
  49. ncbi request reprint Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease
    Shiobhan R Weston
    Department of Medicine, University of California at San Francisco, USA
    Hepatology 41:372-9. 2005
    ..Clinicians need to be aware of the variable presentations of NAFLD in different racial and ethnic groups...
  50. ncbi request reprint Treating chronic hepatitis B infection in patients who are pregnant or are undergoing immunosuppressive chemotherapy
    Norah A Terrault
    Division of Gastroenterology, University of California San Francisco, 513 Parnassus Avenue, San Francisco, CA 94143, USA
    Semin Liver Dis 27:18-24. 2007
    ....
  51. ncbi request reprint Longitudinal effect of antiretroviral therapy on markers of hepatic toxicity: impact of hepatitis C coinfection
    Audrey L French
    CORE Center Cook County Hospital, Rush Medical College, Chicago, IL 60612, USA
    Clin Infect Dis 39:402-10. 2004
    ..65% to increases of 7.57% of the ULN per year; P values of.19-.71). Our findings lend support to assertions that antiretroviral therapy is safe for women with HCV infection...
  52. ncbi request reprint Should HCV-related cirrhosis be a contraindication for retransplantation?
    Scott W Biggins
    Liver Transpl 9:236-8. 2003
  53. pmc Peginterferon pharmacokinetics in African American and Caucasian American patients with hepatitis C virus genotype 1 infection
    Charles D Howell
    University of Maryland Baltimore School of Medicine, Baltimore, Maryland 21201, USA
    Clin Gastroenterol Hepatol 6:575-83. 2008
    ....
  54. ncbi request reprint Protective antibody levels and dose requirements for IV 5% Nabi Hepatitis B immune globulin combined with lamivudine in liver transplantation for hepatitis B-induced end stage liver disease
    Rolland C Dickson
    Division of Gastroenterology and Hepatology, Mayo Clinic Foundation, Jacksonville, FL 32216, USA
    Liver Transpl 12:124-33. 2006
    ..In conclusion, this study provides a rationale for the use of lower HBIg doses in HBV patients with suppressed replication undergoing LT...
  55. doi request reprint Sustained and focused hepatitis B virus nucleocapsid-specific T-cell immunity in liver transplant recipients compared to individuals with chronic and self-limited hepatitis B virus infection
    Florian Bihl
    Division of Gastroenterology and Hepatology, University Hospital of Geneva, Geneva, Switzerland
    Liver Transpl 14:478-85. 2008
    ..Thus, the profile of the cellular immunity against HBV was in immune suppressed patients similar to subjects with chronic HBV infection with suppressed HBV-DNA...
  56. ncbi request reprint Clinical evaluation (Phase I) of a human monoclonal antibody against hepatitis C virus: safety and antiviral activity
    Eithan Galun
    Goldyne Savad Institute of Gene Therapy, Hadassah Hebrew University Hospital, Jerusalem, Israel
    J Hepatol 46:37-44. 2007
    ..A Phase 1 clinical trial was designed to test safety, tolerability, and antiviral activity of HCV-AB68 in patients with chronic HCV-infection...
  57. ncbi request reprint The changing epidemiology and natural history of hepatitis C virus infection
    Stephanie R Bialek
    Division of Viral Hepatitis, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, USA
    Clin Liver Dis 10:697-715. 2006
    ..Emerging risk factors for disease progression include steatosis, insulin resistance (and factors associated with the metabolic syndrome), and host genetics...
  58. ncbi request reprint Antiviral therapy in liver transplant recipients: is SVR the only endpoint that matters?
    Alexander Kuo
    J Hepatol 46:359-61. 2007
  59. ncbi request reprint Burden of liver disease in the United States: summary of a workshop
    W Ray Kim
    Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Hepatology 36:227-42. 2002
  60. pmc Outcomes of donor evaluation in adult-to-adult living donor liver transplantation
    James F Trotter
    Department of Surgery, University of Colorado, Denver, CO, USA
    Hepatology 46:1476-84. 2007
    ..Other predictors of donor acceptance included earlier year of evaluation and transplant center...
  61. ncbi request reprint Sex and hepatitis C
    Norah A Terrault
    Am J Gastroenterol 100:825-6. 2005

Research Grants1

  1. Resistance to Antiviral Therapy in Chronic Hepatitis C
    Norah Terrault; Fiscal Year: 2005
    ..Moreover, the methodologies developed for patient outreach within the context of this collaborative study will serve as a model for enhancing participation of African Americans in clinical research. ..